The Japanese Daiichi Sankyo has announced that they are preparing to go into Pha
se 1 trials for their mRNA vaccine sometime in late March.
Over in China, there are a handful of companies also working on mRNA vaccines, t
hough they are probably further behind.
Some of the bigger drug makers in China are buying minority stakes in some of th
ese younger start-ups.
However, while the science is known, it requires various building blocks to deve
lop a vaccine.
For mRNA, for example, one key technology is the ability to produce the right ty
pe of fatty lipids to protect the mRNA, and also serve a dual purpose of stimula
ting the deeper and more complex immune response such as trhe production of T ce
lls and neutralising antibodies.
https://bit.ly/3vgDBCg
日本第一三共公司將在3月底
進行一期的mRNA疫苗試驗
在中國也有公司在做mRNA疫苗
只是進度比較後面
一些中國的大公司正在買年輕公司的股份
然而，在科學上，需要各種成分研發疫苗
例如mRNA疫苗
關鍵科技是生產正確的脂肪來保護RNA
還有更複雜的免疫反應
例如T細胞的產生及中和抗體
所以何晶接下來會投資
正在研發mRNA疫苗的公司嗎
她的眼光不是一項很好嗎！！！
未來會有更多mRNA疫苗！！！